Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1988 Jan;26(1):13–17. doi: 10.1128/jcm.26.1.13-17.1988

Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.

A L Barry 1, R N Jones 1
PMCID: PMC266166  PMID: 3343304

Abstract

For in vitro susceptibility tests with cefoperazone and sulbactam (a beta-lactamase inhibitor), 75/30-micrograms disks may be used with the interpretive zone size breakpoints that are currently used for 75-micrograms cefoperazone disks. For dilution tests, a 2:1 ratio of cefoperazone to sulbactam is recommended. For quality control purposes, MIC limits that are used to monitor cefoperazone tests were also applied to tests with the combination of drugs. For gram-negative control strains, zone size limits were calculated to be 1 mm smaller than those used for cefoperazone disks. To monitor the sulbactam portion of the combination, Acinetobacter calcoaceticus subsp. anitratus ATCC 43498 was selected; zones with 75/30-micrograms disks were 26 to 32 mm in diameter, and broth microdilution MICs ranged from 1.0/0.5 to 8.0/4.0 micrograms/ml. With cefoperazone alone, MICs for Acinetobacter calcoaceticus subsp. anitratus were 16 to 64 micrograms/ml and zones ranged from 14 to 18 mm in diameter. For anaerobic dilution tests, only Bacteroides thetaiotaomicron ATCC 29741 is recommended for cefoperazone-sulbactam; MICs ranged from 8.0/4.0 to 32/16 micrograms/ml.

Full text

PDF
13

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C., Jacobs M. R., Spangler S. K., Yamabe S. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Antimicrob Agents Chemother. 1986 Nov;30(5):789–791. doi: 10.1128/aac.30.5.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry A. L., Gavan T. L., Jones R. N., Ayers L. W., Fuchs P. C., Gerlach E. H., Thornsberry C. Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid. Diagn Microbiol Infect Dis. 1987 May;7(1):83–87. doi: 10.1016/0732-8893(87)90076-9. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Jones R. N., Packer R. R. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors. J Antimicrob Chemother. 1986 Jan;17(1):125–127. doi: 10.1093/jac/17.1.125. [DOI] [PubMed] [Google Scholar]
  4. Crosby M. A., Gump D. W. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production. Antimicrob Agents Chemother. 1982 Sep;22(3):398–405. doi: 10.1128/aac.22.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. English A. R., Retsema J. A., Girard A. E., Lynch J. E., Barth W. E. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Antimicrob Agents Chemother. 1978 Sep;14(3):414–419. doi: 10.1128/aac.14.3.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fu K. P., Neu H. C. Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors. J Antimicrob Chemother. 1981 Mar;7(3):287–292. doi: 10.1093/jac/7.3.287. [DOI] [PubMed] [Google Scholar]
  7. Gavan T. L., Jones R. N., Barry A. L., Fuchs P. C., Gerlach E. H., Matsen J. M., Reller L. B., Thornsberry C., Thrupp L. D. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study. J Clin Microbiol. 1981 Jul;14(1):67–72. doi: 10.1128/jcm.14.1.67-72.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jones R. N., Barry A. L., Packer R. R., Gregory W. W., Thornsberry C. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination. J Clin Microbiol. 1987 Sep;25(9):1725–1729. doi: 10.1128/jcm.25.9.1725-1729.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jones R. N., Barry A. L., Thornsberry C., Wilson H. W. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests. Am J Clin Pathol. 1985 Oct;84(4):496–504. doi: 10.1093/ajcp/84.4.496. [DOI] [PubMed] [Google Scholar]
  10. Jones R. N., Gavan T. L., Barry A. L., Thornsberry C., Gibbs D. L. Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits. J Clin Microbiol. 1982 May;15(5):777–786. doi: 10.1128/jcm.15.5.777-786.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jones R. N., Wilson H. W., Thornsberry C., Barry A. L. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies. Diagn Microbiol Infect Dis. 1985 Nov;3(6):489–499. doi: 10.1016/s0732-8893(85)80005-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES